

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Canceled)
2. (Currently Amended) A method specifically for detecting and/or quantifying a cytotoxic factor having a gliotoxic activity, associated with multiple sclerosis, in a biological sample, ~~according to which~~ comprising isolating a heterocomplex chosen from the heterocomplex GM2AP/GM2/MRP14 and mutated GM2AP/GM2/MRP14, in which mutated GM2AP corresponds to the sequence SEQ ID No. 2, ~~is isolated~~ from said biological sample.
3. (Original) The method as claimed in claim 2, according to which the heterocomplex is isolated by means of at least one antibody that binds specifically to the heterocomplex, and

said cytotoxic factor is detected and/or quantified by demonstrating the formation of a complex consisting of the heterocomplex and the antibody.
4. (Currently Amended) The method as claimed in ~~claim 3~~ claim 2, according to which the heterocomplex is isolated by means of at least two antibodies that bind specifically to the heterocomplex, and said cytotoxic factor is detected and/or quantified by demonstrating the formation of a complex consisting of the heterocomplex and the two antibodies.
5. (Canceled)
6. (Currently Amended) The method as claimed in ~~claim 2~~ claim 4, according to which the heterocomplex is isolated by means of at least two antibodies, at least one of which binds specifically to GM2AP or mutated GM2AP of the heterocomplex, and at least the other of which binds specifically to MRP14 of the heterocomplex, and said cytotoxic factor is detected and/or quantified by demonstrating the formation of a complex consisting of the heterocomplex and the two antibodies.

7. (Original) The method as claimed in claim 6, according to which at least one of said antibodies is a capture antibody and at least the other said antibody is a detection antibody.

8. (Previously Presented) The method as claimed in claim 2, according to which the biological sample is subjected to a prior treatment comprising:

digesting the proteins of the sample with proteinase K,
inactivating the proteinase K, and
neutralizing the pH.

9. (Previously Presented) The method as claimed in claim 8, wherein inactivating the proteinase K is carried out by precipitation with trichloroacetic acid, and wherein neutralizing the pH is carried out by the addition of a tris-maleate buffer.

10. (Previously Presented) The method as claimed in claim 2, in which the biological sample is selected from the group consisting of serum, plasma, urine and cerebrospinal fluid.

11. (Withdrawn) A composition for detecting and/or quantifying a cytotoxic factor associated with multiple sclerosis, said cytotoxic factor being chosen from the heterocomplex GM2AP/GM2/MRP14 and mutated GM2AP/GM2/MRP14 in which mutated GM2AP corresponds to the sequence SEQ ID No. 2, wherein the composition comprises at least one antibody that binds specifically to the heterocomplex.

12. (Withdrawn) The composition as claimed in claim 11, comprising at least two antibodies that bind specifically to the heterocomplex.

13. (Withdrawn) A reaction mixture for detecting and/or quantifying a cytotoxic factor associated with multiple sclerosis, said cytotoxic factor being chosen from the heterocomplex GM2AP/GM2/MRP14 and mutated GM2AP/GM2/MRP14 in which mutated GM2AP corresponds to the sequence SEQ ID No. 2, wherein the reaction mixture comprises

at least two antibodies, at least one of which binds specifically to GM2AP or mutated GM2AP of the heterocomplex, and at least the other of which binds specifically to MRP14 of the heterocomplex.

14. (Withdrawn) The reaction mixture as claimed in claim 13, wherein at least one of said antibodies is a capture antibody and at least the other of said antibodies is a detection antibody.

15. (Withdrawn) A complex comprising the heterocomplex GM2AP/GM2/MRP14 or mutated GM2AP/GM2/MRP14, said heterocomplex being bound to at least two antibodies, at least one of the antibodies of which is specific for GM2AP or for mutated GM2AP, and at least the other antibody of which is specific for MRP14.